Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment

Completed · Phase 2

Conditions studied: Colorectal Neoplasms

In brief

This study is for patients with metastatic adenocarcinoma arising from the colon or rectum who have received treatment(s) for metastatic disease with subsequent disease progression. Patients who are intolerant to treatment(s) are also included. This is a study for good performance status colorectal cancer patients who have exhausted standard therapy options.

Key facts

Study ID

NCT00313794

Run by

AstraZeneca

People needed

49

Starts

2006-05-01

Expected to finish

2008-06-01

Last updated by the study team

2012-06-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Radiographic evidence of metastatic, progressive disease following standard therapies.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

You may not qualify if…

• Known brain metastases or uncontrolled pleural effusions.
• History of chronic inflammatory or autoimmune disease.

Where it is running

• Research Site — Bessemer, Alabama, United States
• Research Site — Birmingham, Alabama, United States
• Research Site — Birmingham, Alabama, United States
• Research Site — Birmingham, Alabama, United States
• Research Site — Birmingham, Alabama, United States
• Research Site — Birmingham, Alabama, United States
• Research Site — San Francisco, California, United States
• Research Site — San Francisco, California, United States
• Research Site — New York, New York, United States
• Research Site — Lévis, Quebec, Canada
• Research Site — Québec, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.